lncRNA MYLK-AS1 is generally considered to be a tumor-promoting factor, and its decreased expression could inhibit tumorigenesis, such as nephroblastoma, gastric cancer, and hepatocellular carcinoma, through different mechanisms [19, 68–70]. This evidence concerns the gene MYLK and hepatocellular carcinoma.